A Phase I/II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase I/II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Ruxolitinib (Primary) ; Calcineurin inhibitors; Corticosteroids
- Indications Graft-versus-host disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 13 Jan 2019 Planned initiation date (Estimated date of first participant enrollement) changed from 31 Jan 2019 to 30 Apr 2019.
- 30 Nov 2018 Planned initiation date (Estimated date of first participant enrollement) changed to 31 Jan 2019.
- 10 Oct 2018 Status changed from not yet recruiting to recruiting.